Literature DB >> 25170312

First-degree relative risk: in utero levetiracetam and valproate exposure.

David W Loring.   

Abstract

Entities:  

Year:  2014        PMID： 25170312      PMCID： PMC4120384          DOI： 10.5698/1535-7597-14.4.186

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  10 in total

1.  In utero exposure to levetiracetam vs valproate: development and language at 3 years of age.

Authors:  R Shallcross; R L Bromley; C P Cheyne; M García-Fiñana; B Irwin; J Morrow; G A Baker
Journal:  Neurology       Date:  2014-01-08       Impact factor: 9.910

2.  Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.

Authors:  Torbjörn Tomson; Dina Battino; Erminio Bonizzoni; John Craig; Dick Lindhout; Anne Sabers; Emilio Perucca; Frank Vajda
Journal:  Lancet Neurol       Date:  2011-06-05       Impact factor: 44.182

3.  Child development following in utero exposure: levetiracetam vs sodium valproate.

Authors:  R Shallcross; R L Bromley; B Irwin; L J Bonnett; J Morrow; G A Baker
Journal:  Neurology       Date:  2011-01-25       Impact factor: 9.910

4.  Common data elements in epilepsy research: development and implementation of the NINDS epilepsy CDE project.

Authors:  David W Loring; Daniel H Lowenstein; Nicholas M Barbaro; Brandy E Fureman; Joanne Odenkirchen; Margaret P Jacobs; Joan K Austin; Dennis J Dlugos; Jacqueline A French; William Davis Gaillard; Bruce P Hermann; Dale C Hesdorffer; Steven N Roper; Anne C Van Cott; Stacie Grinnon; Alexandra Stout
Journal:  Epilepsia       Date:  2011-03-22       Impact factor: 5.864

5.  Increased rate of major malformations in offspring exposed to valproate during pregnancy.

Authors:  D F Wyszynski; M Nambisan; T Surve; R M Alsdorf; C R Smith; L B Holmes
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

6.  Topiramate dose effects on cognition: a randomized double-blind study.

Authors:  D W Loring; D J Williamson; K J Meador; F Wiegand; J Hulihan
Journal:  Neurology       Date:  2010-12-09       Impact factor: 9.910

7.  The longer term outcome of children born to mothers with epilepsy.

Authors:  N Adab; U Kini; J Vinten; J Ayres; G Baker; J Clayton-Smith; H Coyle; A Fryer; J Gorry; J Gregg; G Mawer; P Nicolaides; L Pickering; L Tunnicliffe; D W Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

Review 8.  Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts.

Authors:  Kimford Meador; Matthew W Reynolds; Sheila Crean; Kyle Fahrbach; Corey Probst
Journal:  Epilepsy Res       Date:  2008-06-18       Impact factor: 3.045

9.  Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.

Authors:  Kimford J Meador; Gus A Baker; Nancy Browning; Morris J Cohen; Rebecca L Bromley; Jill Clayton-Smith; Laura A Kalayjian; Andres Kanner; Joyce D Liporace; Page B Pennell; Michael Privitera; David W Loring
Journal:  Lancet Neurol       Date:  2013-01-23       Impact factor: 44.182

10.  Normal intelligence in children with prenatal exposure to carbamazepine.

Authors:  E Gaily; E Kantola-Sorsa; V Hiilesmaa; M Isoaho; R Matila; M Kotila; T Nylund; A Bardy; E Kaaja; M-L Granström
Journal:  Neurology       Date:  2004-01-13       Impact factor: 9.910
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.